<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622905</url>
  </required_header>
  <id_info>
    <org_study_id>FNMI-002</org_study_id>
    <nct_id>NCT03622905</nct_id>
  </id_info>
  <brief_title>ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease</brief_title>
  <official_title>ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Functional Neuromodulation Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Functional Neuromodulation Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary efficacy objective of this study is to test the hypothesis that DBS-f stimulation&#xD;
      (ON) will slow cognitive and functional progression of AD, as compared to no stimulation&#xD;
      (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated&#xD;
      Alzheimer's disease rating scale (iADRS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Over Time at 12 months on the Ingegrated Alzheimer's Disease Rating Scale (iADRS) [ Time Frame: From Baseline to month 12 ]</measure>
    <time_frame>12 months</time_frame>
    <description>The iADRS is a composite tool that combines scores from the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL). It measures both cognition and function and demonstrates acceptable psychometric properties, and is effective in capturing both disease progression and separation of placebo and active treatment effect. The iADRS score ranges from 0 to 146 with lower scores indicating worse performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time at 12 months on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) [ Time Frame: From Baseline to month 12 ]</measure>
    <time_frame>12 months</time_frame>
    <description>The CDR-SB is a validated clinical assessment of global function in patients with AD. Impairment is scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or &quot;box scores&quot;, can be added together to give the CDR-SB which ranges from 0 to 18 (severe impairment).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>DBS On</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DBS system On</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBS Off</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>DBS System Off</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS-f On</intervention_name>
    <description>Deep Brain Stimulation of the fornix</description>
    <arm_group_label>DBS On</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS Off</intervention_name>
    <description>Deep Brain Stimulation of the fornix turned off</description>
    <arm_group_label>DBS Off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent signed by the subject and caregiver.&#xD;
&#xD;
          2. At least 65 years old&#xD;
&#xD;
          3. Probable Alzheimer's disease according to the National Institute of Aging Alzheimer's&#xD;
             disease Association criteria.&#xD;
&#xD;
          4. Mild dementia according to the Clinical Dementia Rating (CDR) global rating of 0.5 or&#xD;
             1 at screening.&#xD;
&#xD;
          5. ADAS-cog-11 score of 10-24 inclusive at screening AND baseline (with a score ≥ 4 on&#xD;
             ADAS-cog item 1).&#xD;
&#xD;
          6. Confirmation of Alzheimer's disease based on CSF biomarkers.&#xD;
&#xD;
          7. The patient has an available caregiver or other appropriate knowledgeable informant&#xD;
             who can reliably report on daily activities and function and signs the informed&#xD;
             consent for participation as such.&#xD;
&#xD;
          8. Patient must be a good surgical candidate for placement of a deep brain stimulator as&#xD;
             judged by the DBS surgical team.&#xD;
&#xD;
          9. Fluency (oral and written) in the language in which standardized tests will be&#xD;
             administered.&#xD;
&#xD;
         10. The patient is either&#xD;
&#xD;
               1. taking a stable dose of cholinesterase inhibitor (AChEI) medication (donepezil,&#xD;
                  galantamine, or rivastigmine) for at least 60 days prior to signing the informed&#xD;
                  consent form OR&#xD;
&#xD;
               2. the patient has previously had an intolerance/failure to cholinesterase inhibitor&#xD;
                  medications that can be documented AND there is no intention to modify the dose&#xD;
                  over the course of the study (NOTE: These medications may NOT be initiated,&#xD;
                  discontinued or modified during the 12-month control period).&#xD;
&#xD;
                  OR&#xD;
&#xD;
               3. c) a physician has fully discussed the possibility of prescribing cholinesterase&#xD;
                  inhibitors and the physician in collaboration with the patient/caregiver have&#xD;
                  declined trying cholinesterase inhibitors and this discussion and decision are&#xD;
                  fully documented in the patient's medical records. This discussion occurred&#xD;
                  during the course of the patient's care, and not as a component of enrollment or&#xD;
                  discussion of participation in this clinical trial.&#xD;
&#xD;
        AND there is no intention to modify the dose over the course of the study (NOTE: These&#xD;
        medications may NOT be initiated, discontinued or modified after study initiation for the&#xD;
        12-months control period).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. NPI total score ≥ 10 or score ≥ 4 in any NPI domain (clinically significant&#xD;
             neuropsychiatric symptoms). Apathy score ≥ 4 acceptable.&#xD;
&#xD;
          2. Modified Hachinski ischemia scale score &gt; 4 at screening.&#xD;
&#xD;
          3. At risk for suicide in the opinion of the investigator or the subject answers &quot;yes&quot; to&#xD;
             &quot;Suicidal Ideation&quot; Item 4 or 5 on the C-SSRS (at the time of evaluation) at the&#xD;
             screening visit or attempted suicide within the last 2 years.&#xD;
&#xD;
          4. Suffers from a major psychiatric disorder such as schizophrenia, bipolar disorder or&#xD;
             major depressive disorder, or has current alcohol or substance abuse based on&#xD;
             psychiatric consultation at screening visit.&#xD;
&#xD;
          5. History of moderate or more severe traumatic brain injury in the 2 years prior to&#xD;
             signing the consent to participate in the study.&#xD;
&#xD;
          6. History of brain tumor, subdural hematoma, or other clinically significant (in the&#xD;
             judgment of the investigator) space-occupying lesion on CT or MRI.&#xD;
&#xD;
          7. History of seizure disorder.&#xD;
&#xD;
          8. Contraindications for MRI scanning, including implanted metallic devices (e.g.&#xD;
             non-MRI-safe cardiac pacemaker or neurostimulator; some artificial joints metal pins;&#xD;
             surgical clips; or other implanted metal parts), or claustrophobia or discomfort in&#xD;
             confined spaces.&#xD;
&#xD;
          9. Radiation exposure in the 1 year prior to signing the informed consent form that, in&#xD;
             combination with the radiation exposure from this study, would exceed 5 rem.&#xD;
&#xD;
         10. Abnormal cardiovascular or neurovascular disorder that, in the opinion of the&#xD;
             investigator would preclude participation in the study.&#xD;
&#xD;
         11. Currently prescribed or planning to start any amyloid-beta directed antibody drug&#xD;
             (e.g. aducanumab or similar) within the first year following implantation in this&#xD;
             study. Prior use of amyloid-beta directed antibody drugs must be stopped at least 6&#xD;
             months prior to signing consent.&#xD;
&#xD;
         12. Currently prescribed any non-AD medications that, in the opinion of the investigator&#xD;
             would preclude participation in the study.&#xD;
&#xD;
         13. Is unable or unwilling to comply with protocol follow-up requirements.&#xD;
&#xD;
         14. Has a life expectancy of &lt; 1 year.&#xD;
&#xD;
         15. Is actively enrolled in another concurrent clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristen Drake</last_name>
    <phone>214-543-8321</phone>
    <email>kdrake@fxneuromod.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Fosdick</last_name>
    <email>lfosdick@fxneuromod.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalisa Santiago</last_name>
      <phone>602-406-7851</phone>
    </contact>
    <investigator>
      <last_name>Anna Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Ponce, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Romano</last_name>
      <phone>323-442-9869</phone>
      <email>Amanda.Romano@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Darrin Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Joe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Swartz</last_name>
      <phone>352-273-5612</phone>
      <email>Cami.Swartz@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Adolfo Ramirez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Foote, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Samson</last_name>
      <phone>813-974-1201</phone>
      <email>jsamson@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Fils, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yarema Bezchlibnyk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Schwarz</last_name>
      <phone>410-550-9022</phone>
      <email>sschwa48@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William(Stan) Anderson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Lindsay</last_name>
      <phone>314-977-4724</phone>
    </contact>
    <investigator>
      <last_name>Richard Bucholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Grossberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Kampschnieder</last_name>
      <phone>402-559-5134</phone>
      <email>haley.kampschnieder@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel L Murman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aviva Abosch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Blount</last_name>
      <phone>336-713-3133</phone>
      <email>vblount@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Adrian Laxton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Fetter</last_name>
      <phone>412-359-4856</phone>
      <email>Mary.fetter@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Donald Whiting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nestor D Tomycz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Owen Leary</last_name>
      <phone>401-606-8388</phone>
      <email>owen.leary@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Wael Asaad, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Drake, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Umer Akbar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Bernal</last_name>
      <phone>512-270-9039</phone>
      <email>nicole.bernal@austin.utexas.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Buchanan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin Hilsabeck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Gelvoligaya</last_name>
      <phone>713-798-7245</phone>
      <email>lukejan.gelvoligaya@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Ashwin Viswanathan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle York, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Trevino</last_name>
      <phone>210-450-3976</phone>
      <email>trevinoha@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Gabriel de Erausquin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Papanastassiou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasnuva Hoque</last_name>
      <phone>(416) 603-5800</phone>
      <phone_ext>2797</phone_ext>
      <email>Tasnuva.Hoque@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Suneil K Kalia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätmedizin Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Köln</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Weiss</last_name>
      <phone>0049-221-47898842</phone>
      <email>kerstin.weiss@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Veere Visser-Vandewalle, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Özgür Onur, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Krauss</last_name>
      <phone>0511-532-6651</phone>
      <phone_ext>6652</phone_ext>
      <email>krauss.joachim@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Krauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein Campus</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birte Hackelberg</last_name>
      <phone>0049-431-50023989</phone>
      <email>Birte.Hackelberg@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Paschen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thorsten Bartsch, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urte Schneider</last_name>
      <phone>0049-391-6724601</phone>
      <email>Urte.Schneider@dzne.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Voges, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenzel Glanz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut für Seelische Gesundheit (ZI)</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Hornung</last_name>
      <phone>49 06 211 703 3001</phone>
      <email>Silke.Hornung@zi-mannheim.de</email>
    </contact>
    <investigator>
      <last_name>Lutz Frölich, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucrezia Hausner, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schels</last_name>
      <phone>00498941404276</phone>
      <email>Friederike.schels@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Timo Grimmer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Goldhardt, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum München: Klinik und Poliklinik für Psychiatrie und Psychotherapie Alzheimer Therapie- und Forschungszentrum</name>
      <address>
        <city>München</city>
        <zip>D-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ildiko Horvat</last_name>
      <phone>+49 (0)89 4400 55898</phone>
      <email>Ildiko.Horvat@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Robert Perneczky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Schlereth</last_name>
      <phone>0049-931-20124805</phone>
      <email>Schlereth_J@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Cordula Matthies, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Lauer, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>September 30, 2022</last_update_submitted>
  <last_update_submitted_qc>September 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Probable Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

